hVIVO PLC - London-based contract research organisation testing vaccines for infectious and respiratory diseases - Confirms two shareholders, Chair Cathal Friel and Non-Executive Director Brendan Buckley have sold a total around 30.0 million shares in company in a placing at 28 pence per share. Sale represents around 4.4% of the company’s share capital. Friel sells around 26.0 million shares with a resulting holding of 3.1%. Buckley sells around 4.0 million shares with a resulting holding of 0.6%. The selling shareholders have agreed with Cavendish and Peel Hunt not to dispose of any further shares for a period of 12 months without the prior written consent of Cavendish and Peel Hunt.

Current stock price: 27.60 pence

12-month change: up 36%

Copyright 2024 Alliance News Ltd. All Rights Reserved.